How do acute coronary syndrome (ACS) and heart failure (HF) differ regarding pathophysiology, clinical presentation, diagnostic criteria, and treatment?

Differentiating Acute Coronary Syndrome from Heart Failure

Acute coronary syndrome (ACS) and heart failure (HF) are distinct clinical entities with different underlying pathophysiology, but they frequently coexist and can be challenging to differentiate, particularly since ACS precipitates up to one-third of acute HF presentations and their overlap carries significantly higher mortality risk. 1, 2

Pathophysiology

ACS results from acute myocardial ischemia due to coronary artery occlusion or critical stenosis, causing myocardial injury from inadequate oxygen supply. This is a primary vascular event involving plaque rupture, thrombosis, or vasospasm.

Heart Failure is a clinical syndrome of inadequate cardiac output and/or elevated filling pressures, resulting from structural or functional cardiac abnormalities. HF can be caused by multiple etiologies including ischemic cardiomyopathy, valvular disease, hypertension, cardiomyopathies, or arrhythmias 3.

Critical distinction: ACS represents an acute vascular event, while HF represents the heart's inability to meet metabolic demands—though ACS commonly triggers acute decompensated HF (ACS-HF), occurring in 11-25% of ACS presentations 4, 2.

Clinical Presentation

Acute Coronary Syndrome:

• Chest pain/discomfort (pressure, tightness, burning) radiating to arm, jaw, or back
• Diaphoresis, nausea, dyspnea
• Symptoms typically acute onset, often at rest or with minimal exertion
• Caveat: In ACS-HF, chest pain may be atypical or absent, making diagnosis more challenging 1

Heart Failure:

• Dyspnea (exertional progressing to rest), orthopnea, paroxysmal nocturnal dyspnea
• Peripheral edema, weight gain, fatigue
• Jugular venous distension, pulmonary rales, S3 gallop, hepatomegaly
• Symptoms typically progressive over days to weeks (acute decompensation) or chronic

ACS-HF Combined Presentation:

Patients with both conditions more commonly present with:

• Cardiogenic shock and pulmonary edema (significantly higher rates than either alone) 2
• De novo HF (56-61% of ACS-HF cases) 4, 5
• Female sex, older age, diabetes, hypertension, chronic kidney disease 4
• Killip class II-IV on presentation 4

Diagnostic Criteria

Electrocardiography:

ACS diagnostic findings:

• ST-segment elevation (STEMI) ≥1mm in contiguous leads
• ST-segment depression or T-wave inversion (NSTEMI/unstable angina)
• New left bundle branch block

HF findings:

• May show LV hypertrophy, Q waves from prior MI, atrial fibrillation, conduction abnormalities
• Critical pitfall: Pre-existing ECG abnormalities in chronic HF patients can obscure acute ischemic changes 1

Cardiac Biomarkers:

For ACS diagnosis:

• Troponin elevation with dynamic rise/fall pattern indicating acute myocardial injury
• Major diagnostic challenge: Troponins are frequently elevated in acute or chronic HF independent of ACS, making differentiation difficult 1
• Key distinction: Look for dynamic changes and magnitude of elevation—very high troponins with rapid rise/fall suggest ACS

For HF diagnosis:

• BNP >100 pg/mL or NT-proBNP >300 pg/mL supports HF diagnosis 3
• BNP <100 pg/mL or NT-proBNP <300 pg/mL effectively excludes HF 3
• Used for diagnosis, risk stratification, and prognosis 3
• Caveat: Obesity reduces BNP/NT-proBNP sensitivity 3

Imaging:

Echocardiography is essential:

• HF: Demonstrates reduced ejection fraction (<40% in HFrEF), diastolic dysfunction, structural abnormalities, elevated filling pressures
• ACS: May show new wall motion abnormalities in vascular distribution
• ACS-HF: 64% have LVEF <40%, with higher Wall Motion Index Score 6

Coronary angiography:

• Definitive for ACS diagnosis, showing culprit lesion
• Guidelines mandate immediate invasive strategy for ACS-HF regardless of ECG or biomarker findings 1
• ACS-HF patients have higher rates of multi-vessel disease 5

Treatment Approach

Acute Coronary Syndrome:

• Immediate antiplatelet therapy (aspirin, P2Y12 inhibitor)
• Anticoagulation (heparin, LMWH, or fondaparinux)
• Urgent revascularization (PCI for STEMI within 90 minutes, early invasive strategy for high-risk NSTEMI)
• Beta-blockers, ACE inhibitors/ARBs, statins

Heart Failure:

• Diuretics for volume overload (IV furosemide)
• Guideline-directed medical therapy (GDMT): ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors
• Vasodilators (IV nitroglycerin, nitroprusside) for acute decompensation
• Device therapy (ICD, CRT) for chronic HFrEF when indicated 3

Combined ACS-HF Management:

Priority algorithm:

1. Immediate revascularization takes precedence—guidelines recommend immediate invasive strategy regardless of other findings 1

2. Time-sensitive therapies for both conditions simultaneously:

   • Antiplatelet/anticoagulation for ACS
   • Diuretics and vasodilators for HF symptoms
   • Avoid excessive diuresis before catheterization (may worsen hemodynamics)

3. Higher intensity interventions needed:

   • More frequent use of IV nitrates, inotropes, vasopressors 2
   • Higher rates of mechanical ventilation 5
   • Hemodynamic monitoring may be necessary

4. Post-acute management:

   • Aggressive GDMT implementation (ACE inhibitors used in 75% of ACS-HF patients) 4
   • Beta-blockers (though used less frequently in HF patients: 75% vs 82%) 7
   • Newer therapies: SGLT2 inhibitors, ARNI showing promise in post-MI HF 4

Prognostic Implications

ACS-HF carries substantially worse prognosis:

• In-hospital mortality: OR 4.43 (95% CI: 2.52-7.78) 4
• 30-day mortality: 13% vs 8% for HF alone (OR 2.0) 2
• 1-year mortality: Risk ratio 2.1 for HFpEF, 35% for HFrEF 4
• Long-term survival: Equalizes after 30 days, with similar 3-5 year outcomes 2, 5

Risk factors for ACS-HF development:

• Pre-existing HF (4-fold increased risk) 4
• Diabetes (OR 1.23-2.3) 4
• Anterior MI territory (OR 5.47) 6
• Late presentation (>12 hours, OR 3.31) 6
• Female sex, older age, chronic kidney disease 4

The combination of ACS and HF represents a high-risk phenotype requiring aggressive, time-sensitive intervention with both immediate revascularization and optimal medical management for both conditions to reduce the substantially elevated short-term mortality risk.